Peptide Blend
PreclinicalBPC-157 + TB-500 Blend
The BPC-157/TB-500 blend combines two of the most discussed tissue repair peptides into a single formulation. BPC-157 (Body Protection Compound) promotes gut and tissue healing through multiple pathways, while TB-500 (a fragment of Thymosin Beta-4) supports wound healing and cell migration through actin regulation. The combination is widely used in the biohacking and functional medicine communities. However, there are no published studies on the blend itself, the evidence for each peptide exists independently. Here is what the research shows.
Science simplified
BPC-157 and TB-500 are two tissue repair peptides that work through different mechanisms. BPC-157 targets localized injury repair through blood vessel growth and growth factor signaling. TB-500 works more broadly to help cells move to damaged tissue and reduce inflammation. Together they address recovery from two complementary directions. No study has ever tested the combination, all evidence is from the individual compounds.
Best researched for
Tissue repair · injury recovery (individual compounds)
Evidence stage
No combination studies · individual: BPC-157 Human Trials, TB-500 Animal Studies
Approval status
Not approved · both Category 2 restricted
1
Indexed Studies
Preclinical
Evidence Level
None
Human Trial Data
Not Approved
Investigational
PSI OVERVIEW
The BPC-157/TB-500 blend is the most commonly used peptide combination in functional medicine. The logic is straightforward: BPC-157 and TB-500 work through complementary mechanisms, and combining them may produce additive tissue repair effects. PSI rates this blend Preclinical, not because the individual peptides lack evidence, but because the combination itself has essentially zero published research. No study has tested whether BPC-157 and TB-500 together are superior to either alone, whether they interact synergistically, or whether the combination alters the safety profile. Each component should be evaluated based on its individual evidence (BPC-157 at Human Trials, TB-500 at Animal Studies).
Mechanism of Action
In everyday terms: BPC-157 acts like a targeted repair signal at the injury site, promoting new blood vessel growth and tissue rebuilding. TB-500 works more broadly across the whole body, helping cells move to where they are needed and reducing the inflammation that slows healing. Together they address recovery from two different but complementary directions.
The mechanistic rationale for combining BPC-157 and TB-500 rests on their non-overlapping repair pathways. BPC-157 promotes localized angiogenesis and upregulates growth factors (VEGF, EGF, FGF) along with nitric oxide system modulation. TB-500 promotes systemic cell migration through actin regulation (via the LKKTET motif) and reduces inflammation through TNF-α and IL-6 suppression. These mechanisms are genuinely distinct and complementary. However, the theoretical complementarity has never been tested in a combination study.
What is the BPC-157/TB-500 blend researched for?
The blend is used for specific applications based on the individual compound evidence. Here is the evidence level for the combination.
Tissue Repair
PreclinicalThe rationale combines BPC-157's multi-pathway healing with TB-500's actin-mediated cell migration. No study has tested the combination. Individual evidence: BPC-157 Human Trials, TB-500 Animal Studies.
Injury Recovery
PreclinicalCommunity reports suggest the blend may accelerate recovery from musculoskeletal injuries. This is anecdotal, no controlled data exists for the combination.
Gut Healing
PreclinicalBPC-157 has preclinical gut healing evidence individually. Whether TB-500 adds benefit for gut applications is unknown.
PSI Verdict
Supported by evidence
BPC-157 and TB-500 have independent evidence bases documenting tissue repair properties through complementary mechanisms. BPC-157 acts through multiple pathways including VEGF, NO, and GH signaling. TB-500 promotes cell migration through actin regulation. The rationale for combining them is pharmacologically plausible.
Not yet established
Whether the combination produces additive, synergistic, or antagonistic effects. Zero published studies test the blend. Whether the components interact pharmacokinetically when co-administered. Whether the combination alters the safety profile of either component. Optimal ratio and dosing of the blend.
Confidence level
Very low for the combination. Refer to BPC-157 (Human Trials) and TB-500 (Animal Studies) individual pages for component-level evidence. Preclinical for the blend reflects the complete absence of combination data.
Component Structures
Molecular data for each component.
Research Evidence
Key patterns from indexed research.
Zero published studies test the BPC-157/TB-500 combination, the blend's evidence level (Preclinical) reflects the complete absence of combination data
Each component has its own evidence base, but the combination itself is untested in any published preclinical or clinical study
BPC-157 and TB-500 work through genuinely distinct mechanisms, angiogenesis/growth factors vs actin regulation/cell migration
This mechanistic complementarity is the theoretical rationale for combining them. It is pharmacologically plausible but unproven
This is the most commonly used peptide combination in the functional medicine and biohacking communities
Commercial popularity has far outpaced the scientific evidence for the combination
Each component should be evaluated based on its individual evidence: BPC-157 (Human Trials, 212+ studies) and TB-500 (Animal Studies, 1,050+ studies via thymosin beta-4)
The blend rating of Preclinical does not diminish the individual compound ratings. It reflects that the combination is unstudied
Safety Profile
No safety data exists for the BPC-157/TB-500 combination. Each component has preclinical safety data independently. Both individual peptides were placed on the FDA's Category 2 restricted list and are expected to return to Category 1 following the February 2026 HHS announcement. The combination product has no separate regulatory status.
Comparison: Blend vs Individual Components
The key question is whether the blend offers advantage over either component alone. Without combination data, this cannot be answered. Each component has its own independent evidence profile.
Frequently Asked Questions
Questions to Ask Your Doctor
Explore Related Research
Side-by-side research comparisons with related compounds.
How to Choose
Decision guidance based on existing evidence, not a recommendation.
Looking for a physician who specializes in peptide therapy?
Browse the PSI Physician DirectoryMedical Disclaimer
The BPC-157/TB-500 blend is an investigational combination with no published clinical data. Both components are on the FDA Category 2 list. This page is for educational purposes only and does not constitute medical advice. PSI aggregates publicly available research.